A Patented Blend of Vitamin B-12, Resveratrol, EGCG (green tea extract) and Melatonin with proven scientific results
Chairman & CEO
Chris Efessiou is an experienced, forward-thinking executive, entrepreneur, board director, and a partner in the consulting firm Newport LLC. A recognized expert in transforming science-based endeavors into successful commercial enterprises, he has advised, managed, developed and commercialized more than 40 new products and services in the global healthcare, life sciences, and consumer product markets, including Mucinex, Flonase, Zantac, and others. Chris is a founding mentor of the Maryland Tech Council Venture Mentoring Service, and an advisor to the National Institutes of Health Commercialization Acceleration Program.
Bill is a seasoned financial professional with significant CFO experience in both the public and private sector, including ten start-ups. He has raised funds through private equity, IPO and public debt offerings with transaction sizes ranging from $2 million to $175 million. Bill is also a partner in the consulting firm Newport, LLC.
Director & Co-Founder
Don has over 30 years in senior life science leadership positions within major corporations, consulting firms, and start-ups. Throughout his career, his focus has been on identifying, assessing, acquiring, licensing, and commercializing technology platforms that address significant unmet medical needs. He has led the launch of over ten consumer healthcare products. Don is also a partner in Newport, LLC and The Co-Investment Partnership, LLC.
Director & Co-Founder
Ken is the President and CEO of TDSC. He has been pioneering in topical delivery since 1990 and oversees both operations and technical development and is the co-inventor of the TDSC technology. Additionally, in 2001, he formed the Langford Research Institute and started a fully funded academic and research collaboration with the William Harvey Research Institute at St. Bartholomew’s and Queen Mary’s Medical College, University of London. Mr. Kirby has personally directed the preclinical and clinical research efforts with the Harvey encompassing 19 trials of 17 varied compounds and seven human trials.
Dr. Olcese is a Professor of Biomedical Sciences, Neuroscience and Molecular Biophysics at Florida State University College of Medicine. With over 200 peer-reviewed articles he is an acknowledged authority in the circadian clock and related hormones. He has published several comprehensive investigations of specific hormones evaluating their “protective” effects on long-term cognitive performance, brain Aβ levels/deposition, cytokine levels, and expression of antioxidant enzymes. Previously, James was a Professor at the University of Hamburg.